UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                                 WASHINGTON D.C.

                                   FORM 10-QSB

      [X]   Quarterly Report Pursuant to Section 13 or 15(d) of the Securities
            Exchange Act of 1934, For the Quarter Ended September 30, 2004

      [ ]   Transitional Report Pursuant to Section 13 or 15(d) of the
            Securities Exchange Act of 1934

                          Commission File No. 000-28459

                      ADVANCED PLANT PHARMACEUTICALS, INC.

             (Exact name of Registrant as specified in its charter)


               Delaware                              59-2762023
        -------------------                      -------------------
   (State  of other jurisdiction       (I.R.S. Employer Identification Number)
of  incorporation  or  organization)


                  43 West 33rd Street, New York, New York 10001
                 ----------------------------------------------
                     Address of principal executive offices

        Registrant's telephone number, including area code: 212-695-3334

      Indicate by check mark whether the issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
issuer was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

                                 Yes [X] No [ ]

      As of November 19, 2004, there were issued and outstanding 705,382,359,
shares of Common Stock, $.0007 par value per share.

      Transitional Small Business Disclosure Format

                                 Yes [ ] No [X]


<PAGE>

                      ADVANCED PLANT PHARMACEUTICALS, INC.

                                      INDEX
                                      -----

                                                                          PAGE
                                                                         NUMBER
                                                                         ------

PART I.  FINANCIAL INFORMATION
         ---------------------

Item 1.  Condensed financial statements (unaudited)

         Condensed Balance sheet as of September 30, 2004                      3

         Condensed Statements of operations for the three and three months
                  ended September 30, 2004 and 2003                            4

         Condensed Statements of cash flows for the nine months ended
             September 30, 2004 and 2003                                       5

         Notes to the condensed financial statements                           7

Item 2.  Management's Discussion and Analysis of Financial
         Condition and Results of Operations                                  11

Item 3.  Controls and Procedures                                              15

PART II. OTHER INFORMATION                                                    16
         ----------------

SIGNATURES                                                                    17


<PAGE>

                                     PART I

ITEM 1. CONDENSED FINANCIAL STATEMENTS

                      Advanced Plant Pharmaceuticals, Inc.

                      Unaudited Consolidated Balance Sheets

                                                                   September 30,
                                                                        2004
                                                                   ------------

Assets
Current:
   Accounts receivable, net                                        $      1,008
   Inventory                                                             74,021
   Prepaid Expenses                                                       1,520
                                                                   ------------
                                                                         76,549

Property and equipment, net                                               3,158
Intangible assets, net of impairment losses                             428,360
Due from related companies                                                3,080
Other assets                                                              4,150
                                                                   ------------
Total Assets                                                       $    515,297

Liabilities and Stockholders' Equity
Current:
   Bank overdraft                                                  $      7,071
    Accounts payable                                                    185,580
   Due to stockholder - asset acquisition                             1,315,000
   Loans payable - stockholders                                         936,025
   Accrued expenses                                                     811,419
   Due to distributor                                                   103,500
   Deposits                                                              10,000
                                                                   ------------

   Total Liabilities                                                  3,368,595
                                                                   ------------

Stockholders' Deficiency
   Preferred - $.0007 par value, 10,000,000 shares
     Authorized, 2,500,000 issued and outstanding                         1,750
   Common - $.0007 par value, 880,000,000 shares
     Authorized, 705,248,965 issued and outstanding                     496,474
   Paid-in-capital                                                   14,514,313
   Deficit                                                          (17,865,835)
                                                                   ------------
                                                                     (2,853,298)

Total Liabilities and stockholders' deficiency                     $    515,297
                                                                   ============


   The accompanying notes are an integral part of these financial statements.


<PAGE>

                      Advanced Plant Pharmaceuticals, Inc.

                 Unaudited Consolidated Statements of Operations


<TABLE>
<CAPTION>
                                  Three Months Ended September 30,   Nine Months Ended September 30,
                                  --------------------------------   -------------------------------

                                       2004            2003                2004            2003
                                   ------------    ------------        ------------    ------------
<S>                                <C>             <C>                 <C>             <C>
Revenue                            $      3,557    $      4,151        $     52,532    $     70,660

Cost of Sales                               719           1,163              30,978          30,629
                                   ------------    ------------        ------------    ------------

   Gross Profit                           2,838           2,988              21,554          40,031
                                   ------------    ------------        ------------    ------------

Operating expenses:
   General and administrative           451,769         742,969           3,403,769       1,559,616
                                   ------------    ------------        ------------    ------------

Operating loss                         (448,931)       (739,981)         (3,382,215)     (1,519,585)

Other Income (Expense):
   Miscellaneous income                                                     129,097              --
                                   ------------    ------------        ------------    ------------

Loss before income tax                 (448,931)       (739,981)         (3,253,118)     (1,519,585)

Provision for income tax                    314                                 314             687
                                   ------------    ------------        ------------    ------------

   Net Loss                        $   (449,245)   $   (739,981)       $ (3,253,432)   $ (1,520,272)
                                   ============    ============        ============    ============


Basic and diluted loss per share   $       0.00    $       0.00        $       0.00    $       0.00
                                   ------------    ------------        ------------    ------------

Weighted average common shares
   outstanding                      679,321,429     496,055,460         643,317,578     374,837,987
                                   ============    ============        ============    ============
</TABLE>


   The accompanying notes are an integral part of these financial statements.


<PAGE>

                      Advanced Plant Pharmaceuticals, Inc.

                 Unaudited Consolidated Statements of Cash Flows


                                                       Nine Months Ended
                                                   ----------------------------
                                                   September 30,   September 30,
                                                       2004            2003
                                                   ------------    ------------

Cash Flows From Operating Activities:
   Loss From Operating Activities                  $   (524,794)   $        295


Cash Flows From Financing Activities:
   Payments for property and equipment                   (3,353)              0
                                                   ------------    ------------
     Net cash used in investing activities               (3,353)              0
                                                   ------------    ------------

Cash Flows From Financing Activities:
    Bank overdraft                                        7,071
    Loans payable to stockholders' - net                176,560         246,494
    Due from related companies                            8,658
    Issuance of common stock                             70,000               0
                                                   ------------    ------------

     Net cash provided by financing activities          262,289         246,494
                                                   ------------    ------------


Net increase in Cash                                   (265,858)        246,789

Cash, Beginning of Period                               265,858             219
                                                   ------------    ------------

Cash, End of Period                                $          0    $    247,008
                                                   ============    ============


Supplemental cash flow information:
   Preferred stock issued for services             $          0    $      1,750
                                                   ============    ============

   Common stock issued for services                $  2,312,567    $  1,432,507
                                                   ============    ============

   Stockholder loans converted to common stock     $    520,000
                                                   ============


   The accompanying notes are an integral part of these financial statements.


<PAGE>

                      Advanced Plant Pharmaceuticals, Inc.

                     Notes to Unaudited Financial Statements


1.    CONDENSED FINANCIAL STATEMENTS

In the opinion of the Company, the accompanying unaudited condensed financial
statements include all adjustments (consisting only of normal recurring
accruals) which are necessary for a fair presentation of the results for the
periods presented. Certain information and footnote disclosure, normally
included in the financial statements prepared in accordance with generally
accepted accounting principles, have been condensed and omitted. The results of
operations for the nine months ended September 30, 2004 are not indicative of
the results of operations for the year ended December 31, 2004. The condensed
financial statements should be read in conjunction with the Company's financial
statements included in its annual Form 10 KSB for the year ended December 31,
2003 and Form 10 QSB for the six months ended June 30, 2004.

2.    STOCK WARRANTS

At September 30, 2004, the Company had outstanding warrants to purchase
33,000,000 shares of the Company's common stock at prices ranging from $.03 to
$.10 per share. The warrants become exercisable in 2005 and expire at various
dates through 2007. A waiver of reservation for 30,000,000 shares was received.
Thus, the remaining 3,000,000 shares of common stock were reserved for that
purpose.

3.    COMMITMENTS AND CONTINGENCIES

The Company has employment agreements with four employees, and a consulting
contract with a key consultant, who are also stockholders of the Company. At
September 30, 2004, the Company has a total liability for accrued salaries to
stockholders of $506,300. There could be certain payroll tax liabilities owed to
the IRS on some of the payments for services to certain consultants that were
paid in prior years, pursuant to these employment agreements.

4.    RELATED-PARTIES STOCK AND ASSET TRANSACTIONS

On January 22, 2004, Management and the Director issued under the 2004 Incentive
Stock Plan ("ISP") 27,700,000 shares of common stock as compensation due under
its agreement with various individuals for marketing consulting services
rendered to the Company, valued at $787,900. As part of the total shares issued,
1,500,000 shares of common stock were issued under the ISP to a related party,
also related to the Director, Mr. C. J. Lieberman ("Related Consultant"). The
value of the consulting services was determined by management to be the market
quoted value of the stock as traded on the NASDAQ, Over the Counter Bulletin
Board, at the time of each board resolution to issue the stock.

On June 4, 2004, the Company had also issued, under the ISP, 5,666,666 shares of
common stock for the performance of various services valued at $56,667, and paid
down $20,000 of loan payable to a stockholder with 2,000,000 shares of common
stock for prior services rendered. Both of these transactions were recorded at
$0.01 per share, the fair market on the date of issuance.

The Director, advanced to the Company his personal funds, or paid expenses on
behalf of the Company. As of September 30, 2004, included on the balance sheet
in "Loans payable - Stockholders" are accrued salaries, consulting and other
expenses paid on behalf of the Company by the Director is a balance due him of
$527,283. This loan payable is non-interest bearing.


<PAGE>

                      Advanced Plant Pharmaceuticals, Inc.

                     Notes to Unaudited Financial Statements


4.    RELATED-PARTIES STOCK AND ASSET TRANSACTIONS (CONTINUED)

On January 2, 2004, the Company and Amazing Nutritionals, Inc., a company of
which the Related Consultant is a shareholder, entered into an asset purchase
agreement whereby the Company sold Amazing Nutritionals all rights, title,
patents, trademarks, processes and related items for a product used for the
treatment of senile dementias (LHM123) in consideration for 3,300,000 shares of
common stock of Amazing Nutritionals.

In 2003, the Company entered in an asset purchase agreement with Amazon Biotech,
Inc., ("Amazon"), a company that trades on the NASDAQ, Over The Counter Bulletin
Board, symbol AMZB.OB. The Company sold all rights, title, patents, trademarks,
processes and related items for a product used for the treatment of AIDS disease
("ABAVCA") for 3 million shares of Amazon and certain future royalty payments,
based on future sales of the product. Amazon also agreed to fund a minimum of
$250,000 towards Phase I/II clinical studies of ABAVCA. The Company is in the
process of doing an appraisal of the stock received from Amazon, in order to
determine the book value of its investment in Amazon. At September 30, 2004,
this investment was recorded at its par value, which is $300.

On April 20, 2004, the Company had issued 800,000 shares of its common stock to
a consultant for services rendered. The amount recorded for these services was
$16,000, or $.02 per share, and was based on the market price on the date of
issuance.

On April 22, 2004, the Company had issued 38,300,000 shares of its common stock
to various consultants for services rendered, valued at $766,000. Also, the
Company converted a loan payable to stockholder into the common stock by
issuance of 25 million shares, resulting in debt reduction of $500,000. In
addition, the Company had issued 25 million shares for consulting services
rendered by a Related Consultant, valued at $500,000. These transactions were
recorded at $0.02 per share based on the market price on the date of issuance.

On April 23, 2004, the Company has cancelled 5,000,000 shares of common stock
which were issued by the Company and held by the transfer agent pending the
completion of contractual services. The shares were cancelled due to
nonperformance of the contract.

During the period ended March 31, 2004, the Company issued 3,000,000 shares in a
private placement to several investors at approximately $.02 per share, for
aggregate cash proceeds of $60,000.

On August 26, 2004, the Company issued 32,666,667 shares of common stock to a
consultant for services rendered. The amount recorded for these services was
$147,000, or $.0045 per share.

On September 23, 2004, the Company issued 11,000,000 shares of common stock to
consultants for services rendered. The amount recorded for these services was
$49,500, or $.0045 per share.

5.    MISCELLANEOUS INCOME

 During the period ended September 30, 2004, the Company has a write off of
prior period's accounts payable in the amount of $129,097, shown as a
miscellaneous income on the condensed statements of operations.


<PAGE>

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

Background

Advanced Plant Pharmaceuticals, Inc. (the "Company") was incorporated in the
State of Delaware in 1986, under the name Ventra Management, Inc. On July 20,
1994, we amended our Certificate of Incorporation to change our name to Advanced
Plant Pharmaceuticals, Inc.

Description of Business

The Company continues to focus on the research and development of plant based
dietary supplements. In July 1999, the Company acquired exclusive rights and
interests to a thirteen-step process, which utilizes virtually all of the
nutrients found in plants to manufacture natural herbal dietary supplements. The
purchase price for the thirteen step process was 12,000,000 shares of common
stock of the Company. The shares were issued on February 13, 2001. Further, the
Company is required to issue an additional 6,000,000 shares of common stock when
marketing of the product commences. The Company intends to use this process to
manufacture products that it hopes to distribute worldwide through various sales
distribution contracts.

On February 28, 2000, the Company entered into an Asset Purchase Agreement with
Dr. Bielory to purchase his various allergy and nasal formulations. This
agreement was approved by the Board of Directors on September 6, 2000. Dr.
Bielory was granted a five year option to purchase an aggregate of 18,000,000
shares of the Company's common stock at an exercise price of $180.00. Dr.
Bielroy exercised an option for 12,000,000 shares in the first quarter of 2001.

Sinusol, being the formulation purchased from Dr. Bielory, is a generalized base
solution for the development of an extensive line of specialty products related
to allergy and sinus conditions. The ingredients include a mixture of gently
pH-balanced essential mineral oils that combat the various symptoms related to
allergies and sinus disorders, including congestions, irritated nasal mucosa and
bacterial and fungal infections. Specialized advanced formulations are being
reviewed for patent submission.

In addition to Sinusol, the Company is also currently marketing its Lo-Chol
product. Lo-Chol's formula is derived from the "whole plant" parts of six
selected plants that work in concert to help tip your lipid balance (good and
bad cholesterol) towards a more normal level. These six plants are
synergistically combined using a proprietary "whole plant technology" (a special
pharmaceutical-grade process) that delivers virtually all the natural
phyto-chemicals and active ingredients in the plants. Unlike almost all other
herbal supplements on the market, Lo-Chol does not contain any extracts.
Instead, it utilizes the entire part of a specific plant that is processed and
standardized to deliver optimum potency and nutritional benefits.

Results of Operations

Nine Months Ended September 30, 2004 Compared to the Nine Months Ended September
30, 2003.

Revenues

Revenues generated during the nine months ended September 30, 2004 aggregated
$52,532, as compared to $70,660 for the nine months ended September 30, 2003.
The decrease of $18,128 in revenues from the comparable period in the prior year
is primarily due to less purchases by our exclusive distributors.

Costs of Goods Sold

Cost of Goods Sold for the nine months ended September 30, 2004, aggregated
$30,978 as compared to $30,629 for the nine months ended September 30, 2003. The
increase of $349 for the nine months ended September 30, 2004 as compared to the
nine months ended September 30, 2003, was primarily due to the use of product in
connection with clinical trials.


<PAGE>

Operating Expenses

Operating Expenses incurred for the nine months ended September 30, 2004
aggregated $3,403,769 as compared to $1,559,616 for the nine months ended
September 30, 2003, which is an increase of $1,844,153. This increase was the
result of payment of finders fees in connection with the sales of our products

Net Loss

The net loss was $3,253,432 for the nine months ended September 30, 2004, as
compared to net loss of $1,520,272 for the nine months ended September 30, 2003,
which represents an increased net loss of $1,733,160. The reason for the
increased net loss is a result of the reasons described above.

Three Months Ended September 30, 2004 Compared to the Three Months Ended
September 30, 2003.

Revenues

Revenues generated during the three months ended September 30, 2004 were $3,557,
as compared to $4,151 for the three months ended September 30, 2003. The
decrease of $594 in revenues from the comparable period in the prior year is
primarily due to less purchases by our exclusive distributors.

Costs of Goods Sold

Cost of Goods Sold for the three months ended September 30, 2004 was $719 as
compared to $1,163 for the three months ended September 30, 2004. The $444
decrease for the three months ended September 30, 2004 was primarily due to
decreased sales.

Operating Expenses

Operating Expenses incurred for the three months ended September 30, 2004,
aggregated $451,769 as compared to $742,969 for three months ended September 30,
2003, which is an decrease of $291,200. This decrease was the result of a
decrease in the payment of finders fees payable in connection with the sales of
our products.

Net Loss

The net loss was $449,245 for the three months ended September 30, 2004, as
compared to net loss of $739,981 for the three months ended September 30, 2003.
The reason for the decreased net loss is a result of the reasons described
above.

Liquidity and Capital Resources

At September 30, 2004, we had working capital deficit of $3,292,046 as compared
with $3,081,675 at December 31, 2003. The increase in the working capital
deficit is primarily the result of an increase in accrued expenses.

We have historically sustained our operations and funded our capital
requirements with the funds received from the sale of our products, loans
received from related parties and the sale of our securities. We will still need
additional investments in order to continue operations. Additional investments
are being sought, but we cannot guarantee that we will be able to obtain such
investments.

Financing transactions may include the issuance of equity or debt securities,
obtaining credit facilities, or other financing mechanisms. However, the trading
price of our common stock and the downturn in the U.S. stock and debt markets
could make it more difficult to obtain financing through the issuance of equity
or debt securities. Even if we are able to raise the funds required, it is
possible that we could incur unexpected costs and expenses, fail to collect
significant amounts owed to us, or experience unexpected cash requirements that
would force us to seek alternative financing. Further, if we issue additional
equity or debt securities, stockholders may experience additional dilution or
the new equity securities may have rights, preferences or privileges senior to
those of existing holders of our common stock. If additional financing is not
available or is not available on acceptable terms, we will have to curtail our
operations again.


<PAGE>

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires management of the Company to
make assumptions, estimates and judgments that affect the amounts reported in
the financial statements, including the notes thereto, and related disclosures
of commitments and contingencies, if any. The Company considers its critical
accounting policies to be those that require the more significant judgments and
estimates in the preparation of the Company's financial statements, including
the following: valuation of inventories and intangible assets, valuation of
stock options and warrants, and valuation of all accrued liabilities including
payroll taxes and other contingent liabilities. Management relies on historical
experience and on other assumptions believed to be reasonable under the
circumstances in making its judgment and estimates. Actual results could differ
materially from those estimates.

ITEM 3 - CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

As of September 30, 2004, we carried out an evaluation of the effectiveness of
the design and operation of its disclosure controls and procedures pursuant to
Exchange Act Rule 13a-14. This evaluation was done under the supervision and
with the participation of our Chief Executive Officer and Principal Financial
Officer. Based upon that evaluation, they concluded that there were material
weaknesses associated with our disclosure controls and procedures in so far as
they were not effective in gathering, analyzing and disclosing information
needed to satisfy our disclosure obligations under the Exchange Act. Our
independent auditors issued a letter at the completion of their review of our
financial statements for the six months ended June 30, 2004, detailing the
following material weaknesses:

      o     Lack of supervision and review regarding the recording of stock
            transactions;
      o     Lack of discipline around the financial reporting;
      o     Lack of financial accounting and reporting knowledge; and
      o     Policies and procedures used to develop accruals and estimates.

As a result of the above, the Company terminated its current accounting
personnel and engaged new accounting personnel to address the issues raised by
our independent auditors. The new accounting personnel have assisted management
in developing procedures, forms, checklists and reporting packages to address
these deficiencies, and management believes progress had been made to improve
our system of internal controls. Additional progress in these areas will
continue through the end of the second quarter of 2005.

Changes in internal controls

During the quarter to which this report relates, there was no change in our
internal control over financial reporting that has materially affected, or is
reasonably likely to materially affect, our internal control over financial
reporting, with the exception of the new policies and procedures instituted in
August 2004 to address the material weaknesses set forth above.


<PAGE>

                                     PART II

ITEM 1 - LEGAL PROCEEDINGS

The Company is a party to an action in the Civil Court of the City of New York,
County of New York, entitled, Bowne of New York City, LLC v. Advanced Plant
Pharmaceuticals. This is an action for unpaid fees for filing the reports of the
Company on EDGAR. The suit seeks $15,805.42 in unpaid fees for filings on the
EDGAR system. The Company disputes the total amount due. If the Company is
unable to work out a resolution of this action, it could have a material affect
upon the Company. Counsel for the Company has been in contact with the
attorney's for Bowne, and it is likely that a resolution will be able to be
reached.

ITEM 2 - CHANGES IN SECURITIES

In July 2004, the Company issued 2,500,000 shares of common stock to three
consultants for services provided.

In September 2004, the Company issued 11,000,000 shares of common stock to two
consultants for services provided.

* All of the above offerings and sales were deemed to be exempt under Rule 506
of Regulation D and Section 4(2) of the Securities Act of 1933, as amended. No
advertising or general solicitation was employed in offering the securities. The
offerings and sales were made to a limited number of persons, all of whom were
accredited investors, business associates of the Company or executive officers
of the Company, and transfer was restricted by the Company in accordance with
the requirements of the Securities Act of 1933. In addition to representations
by the above-referenced persons, we have made independent determinations that
all of the above-referenced persons were accredited or sophisticated investors,
and that they were capable of analyzing the merits and risks of their
investment, and that they understood the speculative nature of their investment.
Furthermore, all of the above-referenced persons were provided with access to
our Securities and Exchange Commission filings.

ITEM 3 - DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None

ITEM 5 - OTHER INFORMATION

None

Item 6. - Exhibits and Reports on Form 8-K

      (a)   Exhibits

      31.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            302 of the Sarbanes-Oxley Act of 2002.

      32.1  Certification of the Chief Executive Officer and Principal Financial
            Officer of Advanced Plant Pharmaceuticals, Inc. pursuant to Section
            906 of the Sarbanes-Oxley Act of 2002.

      (b)   Reports

            None.


<PAGE>

                                   SIGNATURES

      In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

                                Advanced Plant Pharmaceuticals, Inc.


                                By: /s/ David Lieberman
                                    ----------------------------
                                    David Lieberman, Chief Executive Officer and
                                    Principal Financial Officer


Dated: November 22, 2004